iopscience.iop.org

Graphene toxicity as a double-edged sword of risks and exploitable opportunities: a critical analysis of the most recent trends and developments

Adriele Prina-Mello

2-3 minutos

---

2053-1583/4/2/022001

Abstract

Increased production volumes and a broadening application spectrum of graphene have raised concerns about its potential adverse effects on human health. Numerous reports demonstrate that graphene irrespective of its particular form exerts its effects on a widest range of living organisms, including prokaryotic bacteria and viruses, plants, micro- and macro-invertebrates, mammalian and human cells and whole animals in vivo. However, the available experimental data is frequently a matter of significant divergence and even controversy. Therefore, we provide here a critical analysis of the most recent (2015–2016) reports accumulated in the graphene-related materials biocompatibility and toxicology field in order to elucidate the cutting edge achievements, emerging trends and future opportunities in the area. Experimental findings from the diverse in vitro and in vivo model systems are analysed in the context of the most likely graphene exposure scenarios, such as respiratory inhalation, ingestion route, parenteral administration and topical exposure through the skin. Key factors influencing the toxicity of graphene and its complex derivatives as well as potential risk mitigation approaches exploiting graphene physicochemical properties, surface modifications and possible degradation pathways are also discussed along with its emerging applications for healthcare, diagnostics and innovative therapeutic approaches.

Export citation and abstract BibTeX RIS

Access this article

The computer you are using is not registered by an institution with a subscription to this article. Please choose one of the options below.

Make a recommendation

To gain access to this content, please complete the Recommendation Form and we will follow up with your librarian or Institution on your behalf.

For corporate researchers we can also follow up directly with your R&D manager, or the information management contact at your company. Institutional subscribers have access to the current volume, plus a 10-year back file (where available).